Abstract
Lichenoid drug reactions are rare compared to typical morbilliform drug exanthema or urticaria. They are associated with specific drugs or drug families like gold, antimalarial drugs, β‑blockers and angiotensin-converting-enzyme inhibitors. Recent observations included associations with novel drugs such as biologics (e. g. tumour necrosis factor antagonists) and immune checkpoint inhibitors (anti-programme cell death protein 1 antibodies). Lichenoid drug reactions most often resemble lichen planus mainly in areas of ultraviolet-light exposed skin, but also mucosal lichen planus and even bullous lesions may occur.
Keywords:
Anti-PD-1 antibodies; Biosimilars; Gold; Interferons; TNF-α antagonists.
MeSH terms
-
Adrenergic beta-Antagonists / adverse effects
-
Adrenergic beta-Antagonists / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antibodies / adverse effects
-
Antibodies / therapeutic use
-
Antimalarials / adverse effects
-
Antimalarials / therapeutic use
-
Biological Products / adverse effects
-
Biological Products / therapeutic use
-
Biosimilar Pharmaceuticals / adverse effects
-
Biosimilar Pharmaceuticals / therapeutic use
-
Drug Eruptions / diagnosis*
-
Gold Compounds / adverse effects
-
Gold Compounds / therapeutic use
-
Humans
-
Interferons / adverse effects
-
Interferons / therapeutic use
-
Lichenoid Eruptions / chemically induced*
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Antibodies
-
Antimalarials
-
Biological Products
-
Biosimilar Pharmaceuticals
-
Gold Compounds
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
TNF protein, human
-
Tumor Necrosis Factor-alpha
-
Interferons